These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 15850007)

  • 1. Efficacy of imatinib mesylate in a patient with idiopathic hypereosinophilic syndrome and severe heart involvement.
    Anghel G; De Rosa L; Ruscio C; Petti N; Riccardi M; Severino A; Majolino I
    Tumori; 2005; 91(1):67-70. PubMed ID: 15850007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate: a case report.
    Tan D; Hwang W; Ng HJ; Goh YT; Tan P
    Int J Hematol; 2004 Jul; 80(1):75-7. PubMed ID: 15293573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome.
    Cortes J; Ault P; Koller C; Thomas D; Ferrajoli A; Wierda W; Rios MB; Letvak L; Kaled ES; Kantarjian H
    Blood; 2003 Jun; 101(12):4714-6. PubMed ID: 12595304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate.
    Ault P; Cortes J; Koller C; Kaled ES; Kantarjian H
    Leuk Res; 2002 Sep; 26(9):881-4. PubMed ID: 12127565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneity of response to imatinib-mesylate (glivec) in patients with hypereosinophilic syndrome: implications for dosing and pathogenesis.
    Musto P; Falcone A; Sanpaolo G; Bodenizza C; Perla G; Minervini MM; Cascavilla N; Dell'Olio M; La Sala A; Mantuano S; Melillo L; Nobile M; Scalzulli PR; Bisceglia M; Carella AM
    Leuk Lymphoma; 2004 Jun; 45(6):1219-22. PubMed ID: 15360005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective treatment of hypereosinophilic syndrome with imatinib mesylate.
    Salem Z; Zalloua PA; Chehal A; Bitar N; Abboud M; Kadri A; Chami B; Bazarbachi A
    Hematol J; 2003; 4(6):410-2. PubMed ID: 14671612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate.
    Garg A; Duggal L; Aggarwal S; Jain N
    J Assoc Physicians India; 2006 Nov; 54():883-6. PubMed ID: 17249259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to imatinib mesylate in patients with hypereosinophilic syndrome.
    Arefi M; García JL; Briz MM; de Arriba F; Rodríguez JN; Martín-Núñez G; Martínez J; López J; Suárez JG; Moreno MJ; Merino MA; Gutiérrez NC; Hernández-Rivas JM
    Int J Hematol; 2012 Sep; 96(3):320-6. PubMed ID: 22806436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate.
    Coutré S; Gotlib J
    Semin Cancer Biol; 2004 Aug; 14(4):307-15. PubMed ID: 15305431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Complete remission with imatinib mesylate (Glivec) of an idiopathic hypereosinophilic syndrome associated with a cutaneous mastocytosis after failure of interferon-alpha].
    Pottier P; Planchon B; Grossi O
    Rev Med Interne; 2003 Aug; 24(8):542-6. PubMed ID: 12888176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet-derived growth factor receptor inhibition to treat idiopathic hypereosinophilic syndrome.
    Stone RM; Gilliland DG; Klion AD
    Semin Oncol; 2004 Apr; 31(2 Suppl 6):12-7. PubMed ID: 15175999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders.
    Pardanani A; Reeder T; Porrata LF; Li CY; Tazelaar HD; Baxter EJ; Witzig TE; Cross NC; Tefferi A
    Blood; 2003 May; 101(9):3391-7. PubMed ID: 12506022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study.
    Baccarani M; Cilloni D; Rondoni M; Ottaviani E; Messa F; Merante S; Tiribelli M; Buccisano F; Testoni N; Gottardi E; de Vivo A; Giugliano E; Iacobucci I; Paolini S; Soverini S; Rosti G; Rancati F; Astolfi C; Pane F; Saglio G; Martinelli G
    Haematologica; 2007 Sep; 92(9):1173-9. PubMed ID: 17666373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From bedside to bench: treatment for rare blood disorder yields clues to disease mechanism.
    Friedrich MJ
    J Natl Cancer Inst; 2003 Aug; 95(15):1102-3. PubMed ID: 12902432
    [No Abstract]   [Full Text] [Related]  

  • 15. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients.
    Helbig G; Stella-Hołowiecka B; Majewski M; Całbecka M; Gajkowska J; Klimkiewicz R; Moskwa A; Grzegorczyk J; Lewandowska M; Hołowiecki J
    Br J Haematol; 2008 Apr; 141(2):200-4. PubMed ID: 18307562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of myeloid neoplasms associated with PDGFRA rearrangement with imatinib mesylate.
    Sun CY; Hu Y; Chu ZB; Guo T; He J
    Int J Hematol; 2009 Jan; 89(1):66-70. PubMed ID: 19096755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.
    Cools J; DeAngelo DJ; Gotlib J; Stover EH; Legare RD; Cortes J; Kutok J; Clark J; Galinsky I; Griffin JD; Cross NC; Tefferi A; Malone J; Alam R; Schrier SL; Schmid J; Rose M; Vandenberghe P; Verhoef G; Boogaerts M; Wlodarska I; Kantarjian H; Marynen P; Coutre SE; Stone R; Gilliland DG
    N Engl J Med; 2003 Mar; 348(13):1201-14. PubMed ID: 12660384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib mesylate treatment in two patients with idiopathic hypereosinophilic syndrome.
    Payne SM; Kovacs MJ
    Ann Pharmacother; 2004; 38(7-8):1215-8. PubMed ID: 15187212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Complete remission of an idiopathic hypereosinophilic syndrome while using imatinib].
    Wolf D; Gastl G; Rumpold H
    Dtsch Med Wochenschr; 2004 Oct; 129(40):2104-6. PubMed ID: 15455302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate.
    Schaller JL; Burkland GA
    MedGenMed; 2001 Sep; 3(5):9. PubMed ID: 11698916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.